Non Small Cell Lung Cancer Clinical Trials in Washington D.C., District of Columbia

15 studies are recruiting for non small cell lung cancer in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

   Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   George Washington University Cancer Center, Washington D.C., District of Columbia

   Locations

   202 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07195695 on ClinicalTrials.gov

2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University Lombardi Cancer Center, Washington D.C., District of Columbia

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

3. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

   This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown University, Washington D.C., District of Columbia

   Locations

   16 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT07154290 on ClinicalTrials.gov

4. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

   This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C., District of Columbia

   Locations

   38 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04302025 on ClinicalTrials.gov

5. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Washington Hospital Center ( Site 0037), Washington D.C., District of Columbia

   Locations

   216 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

6. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

   The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Washington D.C., District of Columbia

   Locations

   167 in total

   Run by

   AstraZeneca

   See if you can join NCT06350097 on ClinicalTrials.gov

7. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

   The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   52 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06586515 on ClinicalTrials.gov

8. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

   The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   George Washington University Medical Faculty Associates ( Site 4064), Washington D.C., District of Columbia

   Locations

   229 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06077760 on ClinicalTrials.gov

9. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

   This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSC…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Locations

   85 in total

   Run by

   BioNTech SE

   See if you can join NCT07111520 on ClinicalTrials.gov

10. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's i…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Washington DC Veterans Affairs Medical Center, Washington D.C., District of Columbia

    Locations

    372 in total

    Run by

    Pfizer

    See if you can join NCT06758401 on ClinicalTrials.gov

11. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

    This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Georgetown University, Washington D.C., District of Columbia

    Locations

    47 in total

    Run by

    Synthekine

    See if you can join NCT05098132 on ClinicalTrials.gov

12. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sibley Memorial Hospital, Washington D.C., District of Columbia

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

13. Repositioning Immunotherapy in VetArans With Lung Cancer

    This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA Central Office, Washington, DC, Washington D.C., District of Columbia

    Locations

    7 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06275360 on ClinicalTrials.gov

14. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Georgetown University Medical Center, Washington D.C., District of Columbia

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

15. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia

    Locations

    15 in total

    Run by

    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov